Aripiprazole Tablet
Product Images NDC 82009-088

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 82009-088). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure9 (Aripiprazole Fig9)

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo, with the Y-axis representing least-squares mean change in score and the X-axis representing weeks of treatment.*

FDA Label Image

10mg (Aripiprazole 10mg)

Aripiprazole Tablets USP 10 mg oral tablets label showing a package size of 500 tablets. The label includes storage instructions, manufacturer information Ajanta Pharma Limited India, and labeler Quallent Pharmaceuticals Health LLC. The NDC number is 82009-090-05. The label also features pharmacist dispensing instructions and a barcode.*

FDA Label Image

15mg (Aripiprazole 15mg)

Aripiprazole Tablets USP 15 mg oral tablet label for a 500-count package. The label indicates the product is manufactured by Ajanta Pharma Limited and labeled by Quallent Pharmaceuticals Health LLC. It includes storage instructions, the NDC 82009-091-05, pharmacy dispensing note, and a barcode.*

FDA Label Image

2mg (Aripiprazole 2mg)

Label for Aripiprazole Tablets USP 2 mg oral tablets, packaged as 500 tablets. The label includes storage instructions, manufacturer information (Ajanta Pharma Limited, India), and labeler information (Quallent Pharmaceuticals Health LLC). The label also contains NDC 82009-088-05 and a pharmacist advisory to dispense the enclosed Medication Guide.*

FDA Label Image

5mg (Aripiprazole 5mg)

Label for Aripiprazole Tablets USP 5 mg by Quallent Pharmaceuticals Health LLC, containing 500 tablets. The label shows storage instructions, manufacturer Ajanta Pharma Limited India, and includes the NDC 82009-089-05. The tablet strength (5 mg) is prominently displayed with dosage form as tablets. Barcode is also visible.*

FDA Label Image

Figure4 (Aripiprazole Fig4)

A chart titled 'Aripiprazole Fold Change and 90% CI' showing changes in pharmacokinetic parameters AUC and Cmax relative to a reference across special populations, including CYP2D6 metabolizer status, gender, age, hepatic impairment (mild, moderate, severe), and severe renal impairment. The x-axis represents change relative to reference (0.5 to 3.0), and data points with confidence intervals illustrate variability in exposure.*

FDA Label Image

Figure5 (Aripiprazole Fig5)

A chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' illustrating the impact of factors like CYP2D6 metabolizer status, gender, age, hepatic impairment, and severe renal impairment on AUC and Cmax. The x-axis shows change relative to reference, and the y-axis lists these factors with corresponding confidence intervals depicted as bars.*

FDA Label Image

Figure6 (Aripiprazole Figure6)

A Kaplan-Meier curve chart comparing the proportion of subjects experiencing relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows the proportion with relapse. The number of subjects at risk is listed below the x-axis for both groups at various time points.*

FDA Label Image

Figure7 (Aripiprazole Figure7)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over a period of 182 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. Data tables below the graph indicate the number of subjects at risk over time for both groups.*

FDA Label Image

Figure8 (Aripiprazole Figure8)

A line graph comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization with the number of subjects at risk listed below, while the y-axis indicates the proportion with relapse ranging from 0.0 to 1.0. The graph includes two lines: a solid line for Aripiprazole and a dashed line for placebo.*

FDA Label Image

Logo (Aripiprazole Logo)

FDA Label Image

Structure (Aripiprazole Struct)

Chemical structure of Aripiprazole, showing its molecular arrangement including chlorophenyl and quinolinone moieties linked by a piperazine and propoxy chain.*

FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

A pharmacokinetic graph showing the effect of various drugs on Aripiprazole. The x-axis represents fold change relative to reference without interacting drug, ranging from 0.5 to 3.0. The y-axis lists drugs categorized as CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others, with data points indicating changes in AUC and Cmax for Aripiprazole with 90% confidence intervals.*

FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

A chart depicting the effect of various drugs on Aripiprazole pharmacokinetics, showing the fold change and 90% confidence interval in dehydro-Aripiprazole levels relative to a reference without interacting drug. It includes data for CYP3A4 inhibitor (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam), with measurements of AUC and Cmax changes.*

FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

A forest plot chart titled 'Effect of Aripiprazole on other Drugs' showing fold change and 90% confidence intervals for various drugs' pharmacokinetic parameters. The x-axis represents change relative to a reference without interacting drug, ranging from 0.5 to 3.0. Drugs listed include CYP2D6 substrates (dextromethorphan, S- and R-warfarin), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine and O-desmethylvenlafaxine, and escitalopram. The plot shows pharmacokinetic variables such as DMDRP, AUC, Cmax, and INR for these drugs.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.